Cassava Sciences股价盘后大跌 FDA暂停该公司癫痫药物试验

Core Viewpoint - Cassava Sciences' stock price fell 15% to $2.41 after the FDA halted its clinical trials for an epilepsy drug, simufilam, which was intended to treat epilepsy related to tuberous sclerosis complex [1] Group 1: Stock Performance - The stock has seen a cumulative increase of 21% this year prior to the recent decline [1] Group 2: FDA Actions - The FDA issued a clinical hold on Cassava's new drug application and the proposed clinical trial for simufilam, requiring the company to provide additional information [1] - Cassava is expected to address the issues raised by the FDA but no longer anticipates starting the clinical trial for simufilam in the first half of 2026 as originally planned [1]